Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
05 December 2023 - 8:16AM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused
biopharmaceutical company, today announced the closing of its
previously announced underwritten public offering of 9,846,157
common shares, which includes 1,384,615 shares sold upon the full
exercise of the underwriters’ option to purchase additional shares,
and pre-funded warrants to purchase up to 769,230 common shares.
The common shares were offered at a public offering price of $32.50
per common share, and the pre-funded warrants were offered at a
price of $32.4999 per pre-funded warrant, with each pre-funded
warrant having an exercise price of $0.0001. The aggregate gross
proceeds to Xenon from the offering, before deducting underwriting
discounts and commissions and other offering expenses payable by
Xenon, were approximately $345.0 million.
J.P. Morgan, Jefferies, BofA Securities, Stifel,
and RBC Capital Markets acted as joint book-running managers for
the offering.
An automatically effective shelf registration
statement relating to the securities offered in the public offering
described above was filed with the Securities and Exchange
Commission (SEC) on October 4, 2021. The offering was
made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A final
prospectus supplement and accompanying prospectus relating to the
offering was filed with the SEC on November 30, 2023 and
are available on the SEC’s website at www.sec.gov. Copies of
the final prospectus supplement and the accompanying prospectus may
also be obtained by contacting J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, NY
10022, by telephone at (212) 284-2300, or by email at
prospectus_department@jefferies.com; BofA Securities, Attention:
Prospectus Department, NC1-0220-02-25, 201 North Tryon Street,
Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com; Stifel, Nicolaus & Company,
Incorporated, Attention: Syndicate, One Montgomery Street, Suite
3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or
by email at syndprospectus@stifel.com; or RBC Capital Markets, LLC,
Attention: Equity Capital Markets, 200 Vesey Street, New York, NY
10281, by telephone at (877) 822-4089, or by email at
equityprospectus@rbccm.com.
No securities were offered or sold, directly or
indirectly, in Canada or to any resident of Canada.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy the securities being
offered, nor shall there be any sale of the securities being
offered in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
Media/Investor Contacts:Jodi RegtsXenon
Pharmaceuticals Inc.Phone:
604.484.3353Email: investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From May 2024 to Jun 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Jun 2023 to Jun 2024